THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 123 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is 3.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,180,120 | -5.6% | 252,621 | +13.2% | 0.00% | – |
Q2 2023 | $2,310,399 | -39.7% | 223,227 | -36.7% | 0.00% | – |
Q1 2023 | $3,828,997 | -30.0% | 352,903 | -27.7% | 0.00% | -100.0% |
Q4 2022 | $5,473,374 | -9.8% | 487,823 | -18.5% | 0.00% | 0.0% |
Q3 2022 | $6,070,000 | +70.3% | 598,665 | +52.1% | 0.00% | – |
Q2 2022 | $3,565,000 | -44.3% | 393,585 | -41.3% | 0.00% | -100.0% |
Q1 2022 | $6,405,000 | -60.8% | 670,004 | -54.7% | 0.00% | -50.0% |
Q4 2021 | $16,343,000 | +318.0% | 1,479,029 | +179.8% | 0.00% | +100.0% |
Q3 2021 | $3,910,000 | -39.9% | 528,552 | +18.0% | 0.00% | 0.0% |
Q2 2021 | $6,504,000 | +100.6% | 447,970 | +182.0% | 0.00% | – |
Q1 2021 | $3,242,000 | -69.1% | 158,871 | -73.1% | 0.00% | -100.0% |
Q4 2020 | $10,483,000 | +479.2% | 589,981 | +381.8% | 0.00% | – |
Q3 2020 | $1,810,000 | -78.6% | 122,443 | -69.6% | 0.00% | -100.0% |
Q2 2020 | $8,448,000 | -33.2% | 402,535 | -26.5% | 0.00% | -33.3% |
Q1 2020 | $12,656,000 | -19.2% | 547,670 | -9.5% | 0.00% | -25.0% |
Q4 2019 | $15,660,000 | +59.5% | 604,856 | +20.0% | 0.00% | +33.3% |
Q3 2019 | $9,819,000 | +7.5% | 504,008 | -9.9% | 0.00% | +50.0% |
Q2 2019 | $9,130,000 | -41.4% | 559,090 | -18.7% | 0.00% | -50.0% |
Q1 2019 | $15,584,000 | -2.7% | 687,392 | +9.8% | 0.00% | -20.0% |
Q4 2018 | $16,023,000 | +316.6% | 626,151 | +431.9% | 0.01% | +400.0% |
Q3 2018 | $3,846,000 | +66.6% | 117,725 | +15.6% | 0.00% | 0.0% |
Q2 2018 | $2,308,000 | -6.4% | 101,806 | +0.2% | 0.00% | 0.0% |
Q1 2018 | $2,465,000 | -8.2% | 101,652 | +5.6% | 0.00% | 0.0% |
Q4 2017 | $2,684,000 | +24.0% | 96,237 | +52.3% | 0.00% | 0.0% |
Q3 2017 | $2,164,000 | -26.4% | 63,186 | -14.4% | 0.00% | 0.0% |
Q2 2017 | $2,940,000 | -40.5% | 73,806 | -45.0% | 0.00% | 0.0% |
Q1 2017 | $4,942,000 | -36.7% | 134,236 | -45.2% | 0.00% | 0.0% |
Q4 2016 | $7,812,000 | +691.5% | 245,044 | +799.2% | 0.00% | – |
Q3 2016 | $987,000 | +32.5% | 27,250 | -16.9% | 0.00% | – |
Q2 2016 | $745,000 | +406.8% | 32,797 | +319.7% | 0.00% | – |
Q1 2016 | $147,000 | +50.0% | 7,814 | +30.6% | 0.00% | – |
Q4 2015 | $98,000 | +60.7% | 5,983 | +8.0% | 0.00% | – |
Q3 2015 | $61,000 | -78.3% | 5,539 | -74.3% | 0.00% | – |
Q2 2015 | $281,000 | +35.7% | 21,594 | +80.7% | 0.00% | – |
Q1 2015 | $207,000 | -92.1% | 11,951 | -93.2% | 0.00% | -100.0% |
Q4 2014 | $2,621,000 | +19.8% | 175,703 | +85.2% | 0.00% | 0.0% |
Q3 2014 | $2,187,000 | +922.0% | 94,858 | +1310.7% | 0.00% | – |
Q2 2014 | $214,000 | – | 6,724 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
King Wealth Management Group | 22,500 | $583,000 | 0.15% |
Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |